Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Antipsychotika im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Ein Schwerpunkt liegt in der ausführlichen Darstellung der Risiken und Nebenwirkungen der Antipsychotika.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Arasteh O, Nomani H, Baharara H et al (2020) Antipsychotic drugs and risk of developing venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis. Curr Vasc Pharmacol 18(6):632–643
Arranz B, Garriga M, Bernardo M et al (2022) Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use. Adicciones 34(2):110–127
Bartoli F, Riboldi I, Bachi B et al (2021) Efficacy of cannabidiol for ∆-9-tetrahydrocannabinol-induced psychotic symptoms, schizophrenia, and cannabis use disorders: a narrative review. J Clin Med 10(6):1303
Bighelli I, Rodolico A, Siafis S et al (2022) Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. Cochrane Database Syst Rev 8(8):CD14383
Burk BG, Donaldson V, Jackson CW (2022) Paliperidone-associated sialorrhea: a case report with review of current literature. J Clin Psychopharmacol 42(5):480–484
Burschinski A, Schneider-Thoma J, Chiocchia V et al (2023) Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials. World Psychiatry 22(1):116–128
Ceraso A, Lin JJ, Schneider-Thoma J et al (2022) Maintenance treatment with antipsychotic drugs in schizophrenia: a Cochrane systematic review and meta-analysis. Schizophr Bull 48(4):738–740
Chen B, Wang C, Xu X et al (2020) Risk of prolonged corrected QT interval with amisulpride therapy for renal function management in patients with schizophrenia. J Clin Psychopharmacol 40(5):482–486
Comai S, Fuamba Y, Rivolta MC, Gobbi G (2021) Lifetime cannabis use disorder is not associated with lifetime impulsive behavior and aevere violence in patients with schizophrenia spectrum disorders from a high-security hospital. J Clin Psychopharmacol 41(6):623–628
Correll CU, Kim E, Sliwa JK et al (2021) Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs 35(1):39–59
Das N, Faheem A, Shoib S (2022) The facts and fiction of olanzapine-samidorphan fixed dose combination. Alpha Psychiatry 23(4):210–211
Davis JM, Jin H (2022) Choosing an optimal antipsychotic dose for relapse prevention. Schizophr Bull 48(4):723–725
de Leon J, Schoretsanitis G, Smith RL et al (2022) An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry 55(02):e1
Demjaha A, Lappin JM, Stahl D et al (2017) Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med 47(11):1981–1989
DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde e. V.) (Hrsg) (2019) S3-Leitlinie Schizophrenie. AWMF-Register Nr. 038-009. Langfassung, Stand: 15. März 2019. https://www.awmf.org/leitlinien/detail/ll/038-009.html. Zugegriffen: 13. Mai 2023
Dunk LR, Annan LJ, Andrews CD (2006) Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 188:255–263
Galling B, Vernon JA, Pagsberg AK et al (2018) Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand 137(3):187–205
Greger J, Aladeen T, Lewandowski E (2021) Comparison of the metabolic characteristics of newer second generation antipsychotics: brexpiprazole, lurasidone, asenapine, cariprazine, and iloperidone with olanzapine as a comparator. J Clin Psychopharmacol 41(1):5–12
Guinart D, Misawa F, Rubio JM et al (2021) A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand 144(4):329–341
Haller N, Hasan A, Padberg F et al (2022) Transkranielle elektrische Hirnstimulationsverfahren zur Behandlung der Negativsymptomatik bei Schizophrenie [Transcranial electrical brain stimulation methods for treatment of negative symptoms in schizophrenia]. Nervenarzt 93(1):41–50
Harrow M, Jobe TH, Tong L (2022) Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders. Psychol Med 52(13):2681–2691
He L, Yu Y, Zhang L et al (2022) A real-world study of risk factors for QTc prolongation in schizophrenia patients receiving atypical antipsychotics. J Clin Psychopharmacol 42(1):71–74
Hirjak D, Meyer-Lindenberg A, Brandt GA, Dreßing H (2022) Differenzialdiagnostische Unterscheidung zwischen substanzinduzierten und primären Psychosen: Empfehlungen für die allgemeinpsychiatrische und forensische Praxis [Differential diagnostic distinction between substance-induced and primary psychoses: recommendations for general psychiatric and forensic practice]. Nervenarzt 93(1):11–23
Højlund M, Andersen K, Ernst MT et al (2022) Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study. World Psychiatry 21(3):444–451
Hopkins SC, Lew R, Zeni C, Koblan KS (2023) Challenges in the clinical development of non-D2 compounds for schizophrenia. Curr Med Res Opin 39(3):467–471
Howes OD, McCutcheon R, Agid O et al (2017) Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174(3):216–229
Huhn M, Nikolakopoulou A, Schneider-Thoma J et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202):939–951
Kane JM, Schooler NR, Marcy P et al (2020) Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry 77(12):1217–1224 (Erratum in: JAMA Psychiatry 2020 77(12):1310)
Krause M, Zhu Y, Huhn M et al (2018) Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatr Clin Neurosci 268(7):625–639
Krause M, Huhn M, Schneider-Thoma J et al (2019) Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. Eur Neuropsychopharmacol 29(1):32–45
Kruizinga J, Liemburg E, Burger H et al (2021) Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 12(12):CD4044
Kuhlwilm L, Schönfeldt-Lecuona C et al (2020) The neuroleptic malignant syndrome. Acta Psychiatr Scand 142:233–241
Kurdyak P, Mallia E, de Oliveira C et al (2021) Mortality after the first diagnosis of schizophrenia spectrum disorders: a population-based retrospective cohort study. Schizophr Bull 47(3):864–874
Lally J, Tully J, Robertson D et al (2016) Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 171(1–3):215–224
Lally J, McCaffrey C, O’Murchu C et al (2019) Clozapine rechallenge following neuroleptic malignant syndrome: a systematic review. J Clin Psychopharmacol 39(4):372–379
Leucht S, Davis JM (2017) Do antipsychotic drugs lose their efficacy for relapse prevention over time? Br J Psychiatry 211(3):127–129
Leucht S, Samara M, Heres S, Davis JM (2016) Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull 42(Suppl 1):S90–S94
Leucht S, Leucht C, Huhn M et al (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174(10):927–942
Leucht S, Chaimani A, Mavridis D et al (2019) Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. Neuropsychopharmacology 44(11):1955–1966
Leucht S, Bauer S, Siafis S et al (2021) Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis. JAMA Psychiatry 78(11):1238–1248
Leucht S, Chaimani A, Krause M et al (2022) The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis. Lancet Psychiatry 9(11):884–893
Liu CC, Hsieh MH, Chien YL et al (2023) Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2-year randomized controlled trial with a naturalistic cohort. Psychol Med. https://doi.org/10.1017/s0033291723000429
Masood B, Lepping P, Romanov D, Poole R (2018) Treatment of alcohol-induced psychotic disorder (alcoholic hallucinosis) – A systematic review. Alcohol Alcohol 53(3):259–267
Osoegawa C, Gomes JS, Grigolon RB et al (2018) Non-invasive brain stimulation for negative symptoms in schizophrenia: an updated systematic review and meta-analysis. Schizophr Res 197:34–44
Ostuzzi G, Bertolini F, Del Giovane C et al (2021) Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis. Am J Psychiatry 178(5):424–436
Osugo M, Whitehurst T, Shatalina E et al (2022) Dopamine partial agonists and prodopaminergic drugs for schizophrenia: systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev 135:104568
Paul SM, Yohn SE, Popiolek M et al (2022) Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry 179(9):611–627
Pillinger T, McCutcheon RA, Vano L et al (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7(1):64–77
Qubad M, Bittner RA (2023) Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia. Ther Adv Psychopharmacol 13:20451253231158152
Rahman T, Sahrmann JM, Olsen MA et al (2022) Risk of breast cancer with prolactin elevating antipsychotic drugs: an observational study of US women (ages 18–64 years). J Clin Psychopharmacol 42(1):7–16
Reichelt L, Efthimiou O, Leucht S, Schneider-Thoma J (2023) Second-generation antipsychotics and seizures – a systematic review and meta-analysis of serious adverse events in randomized controlled trials. Eur Neuropsychopharmacol 68:33–46
Santos RT, Mullen S, Crouse EL, Adams KS (2023) Comparison of clozapine doses and tolerability in patients with and without concurrent valproic acid. Ment Health Clin 12(6):336–341
Schmidt-Kraepelin C, Feyerabend S, Engelke C et al (2022) Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. Lancet Psychiatry 9(4):291–306
Schneider-Thoma J, Efthimiou O, Huhn M et al (2018) Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry 5(8):653–663
Schneider-Thoma J, Chalkou K, Dörries C et al (2022) Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet 399(10327):824–836
Siskind D, Sharma M, Pawar M et al (2021) Clozapine levels as a predictor for therapeutic response. Acta Psychiatr Scand 144:422–432
Taipale H, Solmi M, Lähteenvuo M et al (2021) Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry 8(10):883–891
Taipale H, Tanskanen A, Tiihonen J (2023) Safety of antipsychotic polypharmacy versus monotherapy in a nationwide cohort of 61,889 patients with schizophrenia. Am J Psychiatry 180(5):377–385
Taylor DM, Smith L, Gee SH et al (2012) Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 125:15–24
Tiihonen J, Mittendorfer-Rutz E, Torniainen M et al (2016) Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 173(6):600–606
Tiihonen J, Mittendorfer-Rutz E, Majak M et al (2017) Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29.823 patients with schizophrenia. JAMA Psychiatry 74(7):686–693
Tiihonen J, Taipale H, Mehtälä J et al (2019) Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 76(5):499–507
Torniainen M, Mittendorfer-Rutz E, Tanskanen A et al (2015) Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 41:656–636
van der Zalm Y, Foldager L, Termorshuizen F et al (2021) Clozapine and mortality: a comparison with other antipsychotics in a nationwide Danish cohort study. Acta Psychiatr Scand 143(3):216–226
Verdoux H, Quiles C, de Leon J (2023) Risks and benefits of clozapine and lithium co-prescribing: a systematic review and expert recommendations. Schizophr Res. https://doi.org/10.1016/j.schres.2023.03.032
Wagner E, Kane JM, Correll CU et al (2020) Clozapine combination and augmentation strategies in patients with schizophrenia – Recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) working Group. Schizophr Bull 46(6):1459–1470
Wagner E, Siskind D, Falkai P et al (2023) Clozapine optimization: a delphi consensus guideline from the treatment response and resistance in psychosis working group. Schizophr Bull. https://doi.org/10.1093/schbul/sbaa060
Weizman S, Shelef A, Bloemhof Bris E, Stryjer R (2021) A double-blind, placebo-controlled trial of bupropion add-on to olanzapine or risperidone in overweight individuals with schizophrenia. J Clin Psychopharmacol 41(6):629–631
Williams AM (2018) Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness. Ment Health Clin 8(5):208–213
Wimberley T, MacCabe JH, Laursen TM et al (2017) Mortality and selfharm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 174:990–998
Wu H, Siafis S, Hamza T et al (2022) Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials. Schizophr Bull 48(3):643–654
Yeh TC, Correll CU, Yang FC et al (2023) Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: a systematic review and network meta-analysis with normalized entropy assessment. Asian J Psychiatr 79:103375
Yoshimura B, Sakamoto S, Sato K et al (2019) Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: secondary analysis of an observational study. Early Interv Psychiatry 13(3):589–597
Yunusa I, Alsumali A, Garba AE et al (2019) Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open 2(3):e190828
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Müller, M.J., Benkert, O. (2023). Antipsychotika. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67685-1_3
Download citation
DOI: https://doi.org/10.1007/978-3-662-67685-1_3
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-67684-4
Online ISBN: 978-3-662-67685-1
eBook Packages: Medicine (German Language)